Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 4/2005

01-05-2005 | Letter to the editor

Selective serotonin reuptake inhibitors in familial Mediterranean fever: are we treating depression or inflammation?

Authors: Levent Özçakar, Ahmet Mesut Onat, Semra Ulusoy Kaymak, Kemal Üreten, Ayşen Akinci

Published in: Rheumatology International | Issue 4/2005

Login to get access

Excerpt

Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent episodes of fever and serositis, i.e. peritonitis, pleuritis, and synovitis. During follow-up of one of our FMF patients, we made a clinical observation and, on further research, found it noteworthy to discuss a relevant explanation for it. …
Literature
1.
Toubi E, Gershoni-Baruch R, Kuten A (2003) Cisplatin treatment triggers familial Mediterranean fever attacks. Tumori 89:80–81
2.
Minami M, Endo T, Hirafuji M, Hamaue N, Liu Y, Hiroshige T, Nemoto M, Saito H, Yoshioka M (2003) Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther 99:149–165CrossRefPubMed
3.
Pivac N, Mück-Seler D, Sagud M, Jakovljevic M, Mustapic M, Mihaljevic-Peles A (2003) Long-term sertraline treatment and peripheral biochemical markers in female depressed patients. Prog Neurol Psychopharmacol Biol Psychiatry 27:759–765CrossRef
4.
Javors MA, Houston JP, Tekell JL, Brannan SK, Frazer A (2000) Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 3:229–235CrossRefPubMed
5.
Abdel-Salam OM, Baiuomy AR, Arbid MS (2004) Studies on the anti-inflammatory effect of fluoxetine in the rat. Pharmacol Res 49:119–131
6.
Capuron L, Dantzer R (2003) Cytokines and depression: the need for a new paradigm. Brain Behav Immun 17:S119–S124CrossRefPubMed
Metadata
Title
Selective serotonin reuptake inhibitors in familial Mediterranean fever: are we treating depression or inflammation?
Authors
Levent Özçakar
Ahmet Mesut Onat
Semra Ulusoy Kaymak
Kemal Üreten
Ayşen Akinci
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2005
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-004-0511-8

Other articles of this Issue 4/2005

Rheumatology International 4/2005 Go to the issue

Case Report

Clinical quiz: A pediatric case presenting with fever and diffuse myalgia

Original article

The prevalence of joint hypermobility among high school students

Case Report

Multifocal osteoarticular tuberculosis: a case report

Original Article

Manometric assessment of esophageal motility in patients with primary Sjögren’s syndrome

Case Report

Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy

Letter to the Editor

Knee arthritis as a rare inaugural manifestation of adult leukemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits